Charles Schwab Investment Management Inc Akero Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 532,596 shares of AKRO stock, worth $17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

532,596

Previous 554,865 4.01%

Holding current value

$17 Million

Previous $13 Million 17.38%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$21.45 - $29.34 $477,670 - $653,372	-22,269 Reduced 4.01%	532,596 $15.3 Million
Q2 2024 Aug 12, 2024	BUY	$18.31 - $24.62 $669,761 - $900,574	36,579 Added 7.06%	554,865 $13 Million
Q1 2024 May 08, 2024	BUY	$17.76 - $31.18 $1.65 Million - $2.89 Million	92,741 Added 21.79%	518,286 $13.1 Million
Q4 2023 Feb 06, 2024	BUY	$11.38 - $50.33 $69,588 - $307,767	6,115 Added 1.46%	425,545 $9.94 Million
Q3 2023 Nov 08, 2023	BUY	$41.19 - $52.25 $5.14 Million - $6.52 Million	124,768 Added 42.34%	419,430 $21.2 Million
Q2 2023 Aug 09, 2023	BUY	$36.89 - $56.88 $2.08 Million - $3.2 Million	56,315 Added 23.63%	294,662 $13.8 Million
Q1 2023 May 11, 2023	BUY	$37.27 - $50.24 $65,222 - $87,920	1,750 Added 0.74%	238,347 $9.12 Million
Q4 2022 Feb 13, 2023	BUY	$33.44 - $54.8 $788,448 - $1.29 Million	23,578 Added 11.07%	236,597 $13 Million
Q3 2022 Nov 14, 2022	BUY	$10.15 - $34.05 $489,189 - $1.64 Million	48,196 Added 29.24%	213,019 $7.25 Million
Q2 2022 Aug 15, 2022	SELL	$8.0 - $15.01 $69,784 - $130,932	-8,723 Reduced 5.03%	164,823 $1.56 Million
Q1 2022 May 13, 2022	SELL	$12.97 - $22.26 $9,156 - $15,715	-706 Reduced 0.41%	173,546 $2.46 Million
Q4 2021 Feb 11, 2022	BUY	$19.87 - $26.24 $176,823 - $233,509	8,899 Added 5.38%	174,252 $3.69 Million
Q3 2021 Nov 16, 2021	BUY	$18.65 - $25.46 $491,613 - $671,125	26,360 Added 18.96%	165,353 $3.7 Million
Q2 2021 Aug 16, 2021	BUY	$24.81 - $32.35 $691,752 - $901,982	27,882 Added 25.09%	138,993 $3.45 Million
Q1 2021 May 17, 2021	BUY	$24.04 - $34.19 $76,423 - $108,690	3,179 Added 2.95%	111,111 $3.22 Million
Q4 2020 Feb 16, 2021	BUY	$25.12 - $29.89 $2,989 - $3,556	119 Added 0.11%	107,932 $2.79 Million
Q3 2020 Nov 13, 2020	BUY	$30.79 - $39.92 $1.75 Million - $2.27 Million	56,868 Added 111.63%	107,813 $3.32 Million
Q2 2020 Aug 14, 2020	BUY	$19.25 - $26.76 $127,415 - $177,124	6,619 Added 14.93%	50,945 $1.27 Million
Q1 2020 May 15, 2020	BUY	$12.8 - $27.05 $103,705 - $219,159	8,102 Added 22.37%	44,326 $940,000
Q4 2019 Feb 07, 2020	BUY	$17.37 - $27.27 $68,350 - $107,307	3,935 Added 12.19%	36,224 $804,000
Q3 2019 Nov 08, 2019	BUY	$16.89 - $29.88 $545,361 - $964,795	32,289 New	32,289 $735,000

Others Institutions Holding AKRO

# of Institutions

190

Shares Held

73.8M

Call Options Held

241K

Put Options Held

647K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.49B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Akero Therapeutics, Inc. Transaction History